3D Bioprinting

Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates

November 15, 2022 Staff

SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional biology (3D biology) company focused...

Brinter Launches Upgraded Pneuma Triaxial Pro “Digital Pneuma Pro“ Bioprinting Head Capable Of Doing Microfluidic Manipulations To Enable More Personalized Tissue Cell Therapy And Transform How Diseases Are Treated

June 22, 2022 user

Currently being piloted with selected customers, the new 3D bioprinting head provides a revolutionary approach to regenerative medicine and replacing...

Meeting The Challenges Of Bioprinting

March 30, 2020 user

3D bioprinting offers opportunities such as testing treatment for diseases using artificially affected tissues, and through using bioink, it’s much...

3D Bioprinting

Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates

Brinter Launches Upgraded Pneuma Triaxial Pro “Digital Pneuma Pro“ Bioprinting Head Capable Of Doing Microfluidic Manipulations To Enable More Personalized Tissue Cell Therapy And Transform How Diseases Are Treated

Meeting The Challenges Of Bioprinting

Erickson Senior Living Standardizes and Modernizes Physical Security Across its Enterprise with Genetec Security Center

Frontera Therapeutics Doses First Patient in a Clinical Trial of FT-003 Gene Therapy for the Treatment of Wet AMD

Inovalon Adds All-payer Claims Management Software to the PointClickCare Marketplace, Expanding Partnership

Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss

Y-mAbs and the European Medicines Agency Reach Agreement on the Pediatric Investigation Plan for Naxitamab

You may have missed